How they will increase the bottomline in shorter duration with 1700 cr debt and 105 cr interest with having business of CDMO Synthesis/ Bio which requires significant amount of cash to burn?
Don’t you think more pain ahead for them in near term if arv demand is not revived!
Paxalovid demand is gone now…
how others think on these points? the valuations are still high with the performance
| Subscribe To Our Free Newsletter |
